Literature DB >> 15612030

The anthracycline antibiotics: antitumor drugs that alter chromatin structure.

Azra Rabbani1, Ron M Finn, Juan Ausió.   

Abstract

Anthracycline antibiotics are an important group of antitumor drugs widely used in cancer chemotherapy. However, despite the increasing interest in these chemotherapeutic agents, their mechanism of action is not yet completely understood. Here, we review what is currently known about the molecular mechanisms involved with special emphasis on the interaction of these drugs with chromatin and its constitutive components: DNA and histones. The evidence suggests that one very important component of the activity of these drugs is the result of these manifold interactions that lead to a chromatin unfolding and aggregation. This chromatin structural disruption is likely to interfere with the metabolic processes of DNA (replication and transcription) and it may play an important role in the apoptosis undergone by the cells upon treatment with these drugs. Copyright 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15612030     DOI: 10.1002/bies.20160

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  34 in total

Review 1.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

2.  Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.

Authors:  Ezequiel Iván Juritz; Juan Pablo Bascur; Daniel Eduardo Almonacid; Fernando Danilo González-Nilo
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

3.  Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.

Authors:  William R Arnold; Javier L Baylon; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2017-12-12       Impact factor: 3.162

4.  Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.

Authors:  Ming-Tsung Lee; Shuk-Mei Ho; Pheruza Tarapore; Irving Chung; Yuet-Kin Leung
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

5.  A new anthracycline-type metabolite from Streptomyces sp. NEAU-L3.

Authors:  Chang Lu; Yue Zhao; Wei-Qi Jia; Hui Zhang; Huan Qi; Wen-Sheng Xiang; Ji-Dong Wang; Xiang-Jing Wang
Journal:  J Antibiot (Tokyo)       Date:  2017-08-16       Impact factor: 2.649

6.  Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma.

Authors:  Raimund Waldner; Claudia Laschan; Alfred Lohninger; Martin Gessner; Heinz Tüchler; Marlies Huemer; Wolfgang Spiegel; Heidrun Karlic
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-08       Impact factor: 4.553

7.  High-Content Screening Comparison of Cancer Drug Accumulation and Distribution in Two-Dimensional and Three-Dimensional Culture Models of Head and Neck Cancer.

Authors:  Feng Shan; David A Close; Daniel P Camarco; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2017-12-07       Impact factor: 1.738

8.  Crystal structure and functional analysis of tetracenomycin ARO/CYC: implications for cyclization specificity of aromatic polyketides.

Authors:  Brian Douglas Ames; Tyler Paz Korman; Wenjun Zhang; Peter Smith; Thanh Vu; Yi Tang; Shiou-Chuan Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-03       Impact factor: 11.205

9.  Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi.

Authors:  Jian-ye Zhang; Li-yang Tao; Yong-ju Liang; Li-ming Chen; Yan-jun Mi; Li-sheng Zheng; Fang Wang; Zhi-gang She; Yong-cheng Lin; Kenneth Kin Wah To; Li-wu Fu
Journal:  Mar Drugs       Date:  2010-04-23       Impact factor: 5.118

10.  iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.

Authors:  Sara De Boo; Joanna Kopecka; Davide Brusa; Elena Gazzano; Lina Matera; Dario Ghigo; Amalia Bosia; Chiara Riganti
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.